Simulations Plus Common Stock Net 2010-2024 | SLP
Simulations Plus common stock net from 2010 to 2024. Common stock net can be defined as the value of common equity ownership.
Simulations Plus Annual Common Stock Net
(Millions of US $) |
| 2024 |
$152 |
| 2023 |
$145 |
| 2022 |
$139 |
| 2021 |
$133 |
| 2020 |
$129 |
| 2019 |
$0 |
| 2018 |
$0 |
| 2017 |
$0 |
| 2016 |
$0 |
| 2015 |
$0 |
| 2014 |
$0 |
| 2013 |
$0 |
| 2012 |
$0 |
| 2011 |
$0 |
| 2010 |
$0 |
| 2009 |
$0 |
Simulations Plus Quarterly Common Stock Net
(Millions of US $) |
| 2024-11-30 |
$154 |
| 2024-08-31 |
$152 |
| 2024-05-31 |
$150 |
| 2024-02-29 |
$148 |
| 2023-11-30 |
$147 |
| 2023-08-31 |
$145 |
| 2023-05-31 |
$144 |
| 2023-02-28 |
$138 |
| 2022-11-30 |
$140 |
| 2022-08-31 |
$139 |
| 2022-05-31 |
$138 |
| 2022-02-28 |
$135 |
| 2021-11-30 |
$135 |
| 2021-08-31 |
$133 |
| 2021-05-31 |
$132 |
| 2021-02-28 |
$131 |
| 2020-11-30 |
$129 |
| 2020-08-31 |
$129 |
| 2020-05-31 |
$0 |
| 2020-02-29 |
$0 |
| 2019-11-30 |
$0 |
| 2019-08-31 |
$0 |
| 2019-05-31 |
$0 |
| 2019-02-28 |
$0 |
| 2018-11-30 |
$0 |
| 2018-08-31 |
$0 |
| 2018-05-31 |
$0 |
| 2018-02-28 |
$0 |
| 2017-11-30 |
$0 |
| 2017-08-31 |
$0 |
| 2017-05-31 |
$0 |
| 2017-02-28 |
$0 |
| 2016-11-30 |
$0 |
| 2016-08-31 |
$0 |
| 2016-05-31 |
$0 |
| 2016-02-29 |
$0 |
| 2015-11-30 |
$0 |
| 2015-08-31 |
$0 |
| 2015-05-31 |
$0 |
| 2015-02-28 |
$0 |
| 2014-11-30 |
$0 |
| 2014-08-31 |
$0 |
| 2014-05-31 |
$0 |
| 2014-02-28 |
$0 |
| 2013-11-30 |
$0 |
| 2013-08-31 |
$0 |
| 2013-05-31 |
$0 |
| 2013-02-28 |
$0 |
| 2012-11-30 |
$0 |
| 2012-08-31 |
$0 |
| 2012-05-31 |
$0 |
| 2012-02-29 |
$0 |
| 2011-11-30 |
$0 |
| 2011-08-31 |
$0 |
| 2011-05-31 |
$0 |
| 2011-02-28 |
$0 |
| 2010-11-30 |
$0 |
| 2010-08-31 |
$0 |
| 2010-05-31 |
$0 |
| 2010-02-28 |
$0 |
| 2009-11-30 |
$0 |
| 2009-08-31 |
$0 |
| 2009-05-31 |
$0 |
| 2009-02-28 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Computer and Technology |
Computer Software |
$0.715B |
$0.070B |
|
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. They have two other businesses, Words+, Inc. and FutureLab, which are based on its proprietary software technologies.
|
